Please Wait.....
Report
Biologic Therapeutic Drugs: Technologies and Global Markets
Market Research Report I 2025-05-14 I 170 Pages I BCC Research
Description
Report Scope
This report provides an overview of the global biologic therapeutic drug market and analyzes market trends. It includes global revenue ($U.S. millions) for base year data for 2023 and estimated data for 2024. The forecast period is 2024 through 2029. The market is segmented based on product type, application, source and region. By product, the market is segmented into monoclonal antibodies, vaccines, peptide hormones, cell and gene therapies and others. By source, it is segmented into mammalian, microbial and others. By application, the market is segmented into oncology, autoimmune diseases, infectious diseases and others. The regions covered in this study are North America, Europe, Asia-Pacific, Middle East and Africa, and South America, focusing on the major countries in these regions. The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.
The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking and share of key players in the global biologic therapeutic drug market. It also has a section dedicated to company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players.
Report Includes
- 49 data tables and 58 additional tables
- An overview of the current and future global markets for biologic therapeutic drugs and technologies
- An analysis of the global market trends, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the size and revenue prospects of the global market, along with a market share analysis by product type, application, source and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
- Evaluation of the ongoing clinical trials and R&D activity for biologics production
- A look at the key drugs on the market and recent approvals, sales statistics and past performance of the top-selling biologics
- An analysis of patents, emerging trends and other developments in the industry
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Company profiles of major players within the industry, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Pfizer Inc., and Bristol-Myers Squibb Co.
Executive Summary
Summary:
The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029.
The pharmaceutical industry is undergoing tremendous transformations by focusing more on targeted and personalized therapies. The industry is witnessing a shift from traditional synthetic drugs to biologic therapeutic drugs, which are more efficacious, have better patient outcomes and improve quality of life. Biologic drugs are primarily classified into monoclonal antibodies; vaccines; peptide hormones; cell and gene therapies; and others, which include protein therapeutics (e.g., cytokines, enzymes, blood factors, fusion proteins) and other drugs (e.g., RNA-based therapies).
The biopharmaceutical industry has recently been witnessing tremendous growth due to the increasing demand for innovative therapies, such as monoclonal antibodies, cell and gene therapies and vaccines. The demand for these therapies is primarily driven by such factors as the increasing prevalence of chronic diseases, rising healthcare expenditures, increasing awareness, novel product launches and strong pipelines. The biologic approvals by the U.S. Food and Drug Administration (FDA) are increasing year on year, and 2023 was marked by the approval of two breakthrough therapies: the gene editing therapy Casgevy from Vertex Pharmaceutical and Leqembi (lecanemab) from Eisai Inc.
The global biologic therapeutic drug market was valued at $456.9 billion in 2023, and it is expected to grow at a compound annual growth rate (CAGR) of 9.7% during the forecast period from 2024 to 2029. The entry of biosimilars into the market is expected to erode the revenues of the current branded products upon patent expiry. The complex manufacturing process, a lack of skilled workforce and high development costs translate to a high cost of therapy, which acts as a major barrier to the market.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Technological Advances
Conclusion
Chapter 2 Market Overview
Overview
Biologic and Synthetic Drug Comparison
Biologic Manufacturing
Biopharmaceutical Manufacturing Process
Macroeconomic Factors Analysis
Porter's Five Forces Analysis
Supply Chain Analysis
Cell and Gene Therapy Supply Chain
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Growing Demand for Biologics
Rising Investments in Biopharmaceuticals
Product Development Collaborations and Agreements
Transition Toward Personalized Medicines
Rising Aging Population and the Growing Prevalence of Chronic Diseases
Market Restraints
Emergence of Biosimilars
Complex Manufacturing, Lack of Skilled Professionals and High Production Costs
Market Opportunities
Rising Demand for Biopharmaceuticals in Emerging Countries
Technological Innovations in Biologics
Chapter 4 Regulatory Landscape
U.S. Approval Process
European Union Approval Process
Asia-Pacific Approval Process
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Advances in Monoclonal Antibodies
Antibody-Drug Conjugates
Bispecific Antibodies
Nanobodies
Single-Chain Variable Fragments Antibodies
Antibody Mimetics
Antibody Fusion Proteins
Advances in Vaccines
Advances in Cell and Gene Therapies
Chapter 6 Market Segmentation Analysis
Overview
Segmentation Breakdown
Market Analysis by Product Type
Monoclonal Antibodies
Vaccines
Peptide Hormones
Cell and Gene Therapy
Others
Market Analysis by Source Type
Mammalian
Microbial
Others
Market Analysis by Application
Oncology
Autoimmune Disease
Infectious Diseases
Others
Geographic Breakdown
Market Analysis by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Overview
Highest Selling Biologic Therapeutic Drugs
Market Share Analysis
Monoclonal Antibodies
Vaccines
Peptide Hormones
Cell and Gene Therapy
Strategic Initiatives
Agreements, Collaborations and Partnerships
Acquisitions
Other Strategies
Chapter 8 Sustainability in Biologics Therapeutic Drug Market: An ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives
Environmental
Social and Governance Initiatives
ESG Risk Ratings
Concluding Remarks
Chapter 9 Appendix
Research Methodology
Emerging Start-ups/Market Disruptors
Sources
Abbreviations
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
NOVARTIS AG
NOVO NORDISK A/S
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
List of Tables
Summary Table : Global Market for Biologic Therapeutic Drugs, by Region, Through 2029
Table 1 : Global Incidence and Mortality Cancer Rates, by the WHO Region, 2022
Table 2 : Global Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 3 : Top-Selling Monoclonal Antibodies, in 2023
Table 4 : Global Market for Monoclonal Antibodies, by Region, Through 2029
Table 5 : Global Market for Vaccines, by Region, Through 2029
Table 6 : Global Market for Peptide Hormones, by Region, Through 2029
Table 7 : Cell and Gene Therapy Approvals, 2023 and 2024
Table 8 : Global Market for Cell and Gene Therapy, by Region, Through 2029
Table 9 : Global Market for Other Biologic Drugs, by Region, Through 2029
Table 10 : Global Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 11 : Global Market for Mammalian Cells, by Region, Through 2029
Table 12 : Global Market for Microbial Cells, by Region, Through 2029
Table 13 : Global Market for Other Cells, by Region, Through 2029
Table 14 : Global Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 15 : Global Market for Biologic Therapeutic Drugs in Oncology, by Region, Through 2029
Table 16 : Global Market for Biologic Therapeutic Drugs for Autoimmune Diseases, by Region, Through 2029
Table 17 : Global Market for Biologic Therapeutic Drugs for Infectious Diseases, by Region, Through 2029
Table 18 : Global Market for Biologic Therapeutic Drugs for Other Diseases, by Region, Through 2029
Table 19 : Global Market for Biologic Therapeutic Drugs, by Region, Through 2029
Table 20 : North American Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 21 : North American Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 22 : North American Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 23 : North American Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 24 : FDA-Approved Biologics, 2023
Table 25 : European Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 26 : European Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 27 : European Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 28 : European Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 29 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 30 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 31 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 32 : Asia-Pacific Market for Biologic Therapeutic Drugs, by Country, Through 2029
Table 33 : Biologics Approved in China, in 2023
Table 34 : Rest of the World Market for Biologic Therapeutic Drugs, by Product Type, Through 2029
Table 35 : Rest of the World Market for Biologic Therapeutic Drugs, by Source Type, Through 2029
Table 36 : Rest of the World Market for Biologic Therapeutic Drugs, by Application Type, Through 2029
Table 37 : Rest of the World Market for Biologic Therapeutic Drugs, by Sub-Region, Through 2029
Table 38 : Agreements, Collaborations and Partnerships in the Biologic Therapeutic Drug Market, 2022-2025
Table 39 : Acquisitions in the Biologic Therapeutic Drug Market, 2022-2024
Table 40 : Others Strategic Initiatives in the Biologic Therapeutic Drug Market, 2022-2024
Table 41 : Environmental Initiatives by Various Biologic Therapeutic Drug Manufacturers
Table 42 : Key Social and Governance Issues Biologic Therapeutic Drug Market
Table 43 : ESG Risk Rankings for Biologic Therapeutic Drug Companies, 2023
Table 44 : List of a Few Emerging Startups in the Biologic Therapeutic Drugs Market
Table 45 : Information Sources in this Report
Table 46 : Abbreviations Used in the Global Biologic Therapeutic Drugs Market
Table 47 : AbbVie Inc.: Company Snapshot
Table 48 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 49 : AbbVie Inc.: Product Portfolio
Table 50 : AbbVie Inc.: News/Key Developments, 2022-2024
Table 51 : Amgen Inc.: Company Snapshot
Table 52 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 53 : Amgen Inc.: Product Portfolio
Table 54 : Amgen Inc.: News/Key Developments, 2021-2024
Table 55 : AstraZeneca: Company Snapshot
Table 56 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 57 : AstraZeneca: Product Portfolio
Table 58 : AstraZeneca: News/Key Developments, 2021?2024
Table 59 : Bristol-Myers Squibb Co.: Company Snapshot
Table 60 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 61 : Bristol-Myers Squibb Co.: Product Portfolio
Table 62 : Bristol-Myers Squibb Co.: News/Key Developments, 2022-2025
Table 63 : Eli Lilly and Co.: Company Snapshot
Table 64 : Eli Lilly and Co.: Financial Performance, FY 2023 and 2024
Table 65 : Eli Lilly and Co.: Product Portfolio
Table 66 : Eli Lilly and Co.: News/Key Developments, 2023 and 2024
Table 67 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 68 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 69 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 70 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 71 : Gilead Sciences Inc.: Company Snapshot
Table 72 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 73 : Gilead Sciences Inc.: Product Portfolio
Table 74 : Gilead Sciences Inc.: News/Key Developments, 2022?2024
Table 75 : GSK PLC.: Company Snapshot
Table 76 : GSK PLC.: Financial Performance, FY 2023 and 2024
Table 77 : GSK PLC.: Product Portfolio
Table 78 : GSK PLC.: News/Key Developments, 2024
Table 79 : Johnson & Johnson Services Inc.: Company Snapshot
Table 80 : Johnson & Johnson Services Inc.: Financial Performance, FY 2023 and 2024
Table 81 : Johnson & Johnson Services Inc.: Product Portfolio
Table 82 : Johnson & Johnson Services Inc.: News/Key Developments, 2022?2024
Table 83 : Merck & Co. Inc.: Company Snapshot
Table 84 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 85 : Merck & Co. Inc.: Product Portfolio
Table 86 : Merck & Co. Inc.: News/Key Developments, 2022-2024
Table 87 : Novartis AG: Company Snapshot
Table 88 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 89 : Novartis AG: Product Portfolio
Table 90 : Novartis AG: News/Key Developments, 2022-2025
Table 91 : Novo Nordisk A/S: Company Snapshot
Table 92 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
Table 93 : Novo Nordisk A/S: Product Portfolio
Table 94 : Novo Nordisk A/S: News/Key Developments, 2021-2025
Table 95 : Pfizer Inc.: Company Snapshot
Table 96 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 97 : Pfizer Inc.: Product Portfolio
Table 98 : Pfizer Inc.: News/Key Developments, 2023-2024
Table 99 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 100 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 101 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 102 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024
Table 103 : Sanofi: Company Snapshot
Table 104 : Sanofi: Financial Performance, FY 2023 and 2024
Table 105 : Sanofi: Product Portfolio
Table 106 : Sanofi: News/Key Developments, 2022-2024
List of Figures
Summary Figure : Global Market Shares of Biologic Therapeutic Drugs, by Region, 2023
Figure 1 : Differences Between Synthetic and Biologic Drugs
Figure 2 : Porter's Five Forces Analysis of the Biologic Therapeutic Drugs Market
Figure 3 : Supply Chain of Biopharmaceutical Drugs
Figure 4 : Market Dynamics of Biologic Therapeutic Drugs
Figure 5 : Venture Averages for Biopharma Therapeutics and Platform Companies, 2010-2024
Figure 6 : Personalized Medicines' Contribution to the Total FDA Approvals, 2015-2023
Figure 7 : Emerging Technologies in Monoclonal Antibodies
Figure 8 : Global Market Shares of Biologic Therapeutic Drugs, by Product Type, 2023
Figure 9 : Global Vaccination Coverage, by Vaccine, 2023
Figure 10 : Global Market Shares of Biologic Therapeutic Drugs, by Source Type, 2023
Figure 11 : Global Market Shares of Biologic Therapeutic Drugs, by Application Type, 2023
Figure 12 : Global Market Shares for Biologic Therapeutic Drugs, by Region, 2023
Figure 13 : North American Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 14 : European Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 15 : Asia-Pacific Market Shares of Biologic Therapeutic Drugs, by Country, 2023
Figure 16 : Rest of the World Market Shares of Biologic Therapeutic Drugs, by Sub-Region, 2023
Figure 17 : Top 10 Blockbuster Biologic Therapeutic Drugs, by Sales Revenue, 2023
Figure 18 : Global Market Shares for Monoclonal Antibodies, by Key Players, 2023
Figure 19 : Global Market Shares for Vaccines, by Key Players, 2023
Figure 20 : Global Market Shares for Peptide Hormones, by Key Players, 2023
Figure 21 : Global Market Shares for Cell and Gene Therapy, by Key Players, 2023
Figure 22 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 23 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 24 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
Figure 25 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 26 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
Figure 27 : AstraZeneca: Revenue Share, by Region/Country, FY 2024
Figure 28 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 29 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 30 : Eli Lilly and Co.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Eli Lilly and Co.: Revenue Share, by Country/Region, FY 2024
Figure 32 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 33 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 34 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 35 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
Figure 36 : GSK PLC.: Revenue Share, by Business Unit, FY 2024
Figure 37 : GSK PLC.: Revenue Share, by Country/Region, FY 2024
Figure 38 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2024
Figure 39 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2024
Figure 40 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
Figure 41 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
Figure 42 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 43 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 44 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2024
Figure 45 : Novo Nordisk A/S: Revenue Share by Country/Region, FY 2024
Figure 46 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 47 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 48 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 49 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
Figure 50 : Sanofi: Revenue Share, by Business Unit, FY 2024
Figure 51 : Sanofi: Revenue Share, by Country/Region, FY 2024
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security